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Abstract
The Tasmanian devil (Sarcophilus harrisii), the largest extant carnivorous marsupial and
endemic to Tasmania, is at the verge of extinction due to the emergence of a transmissible
cancer known as devil facial tumour disease (DFTD). DFTD has spread over the distribution
range of the species and has been responsible for a severe decline in the global devil popu-
lation. To protect the Tasmanian devil from extinction in the wild, our group has focused on
the development of a prophylactic vaccine. Although this work has shown that vaccine prep-
arations using whole DFTD tumour cells supplemented with adjuvants can induce anti-
DFTD immune responses, alternative strategies that induce stronger and more specific
immune responses are required. In humans, heat shock proteins (HSPs) derived from
tumour cells have been used instead of whole-tumour cell preparations as a source of anti-
gens for cancer immunotherapy. As HSPs have not been studied in the Tasmanian devil,
this study presents the first characterisation of HSPs in this marsupial and evaluates the
suitability of these proteins as antigenic components for the enhancement of a DFTD vac-
cine. We show that tissues and cancer cells from the Tasmanian devil express constitutive
and inducible HSP. Additionally, this study suggests that HSP derived from DFTD cancer
cells are immunogenic supporting the future development of a HSP-based vaccine against
DFTD.
Introduction
The carnivorous marsupial Tasmanian devil (Sarcophilus harrisii) is at risk of extinction due to
a transmissible cancer known as devil facial tumour disease (DFTD). This disease emerged in
northeast Tasmania in 1996 and has spread to almost the entire wild devil population. DFTD
is a unique cancer as the tumour cells themselves are the infectious agent transmitted between
unrelated devils through biting. The disease is characterised by the appearance of large,
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aggressive tumours around the face and neck and most affected animals die from starvation
and organ failure due to metastases. To colonise a new host, DFTD cells evade allorecognition
by downregulating molecules of the major histocompatibility complex class I (MHC-I) and
antigen presenting machinery [1]. However, the existence of other strategies of tumour escape
is largely unknown. A second transmissible cancer was identified in Tasmanian devils in 2014
and was referred to as DFT2 to distinguish from the first DFTD (discovered in 1996, thereby
denoted DFT1). This manuscript relates only to DFT1.
To protect the Tasmanian devil from extinction in the wild our group has focused on the
development of a prophylactic DFTD vaccine. We have shown that vaccine preparations using
whole DFTD tumours cells supplemented with adjuvants can induce humoral responses [2].
Furthermore, we recently showed that DFTD cancer cells can be targeted in vivo by the Tasma-
nian devil’s immune system [3]. These studies demonstrated that Tasmanian devils are able to
mount specific humoral and cellular responses leading to the regression of established DFTD
tumours. The findings also highlighted the feasibility of developing a vaccine. Our approach
used a combination of irradiated DFTD cells or whole cell lysates as antigen, plus adjuvants.
While this vaccine, elicited specific humoral responses, this approach was not completely pro-
tective and tumours developed after challenge with live DFTD cells. As this whole-tumour cell
vaccine showed limited efficacy, alternative strategies that induce stronger and more specific
immune responses are required. An ideal vaccine would be highly immunogenic and enriched
with specific DFTD antigens.
Heat shock proteins (HSPs) have become an attractive source of antigens for cancer immu-
notherapy as an alternative to whole-tumour cell preparations. These proteins are among the
most abundant and ubiquitous intracellular proteins and are highly conserved across species
[4]. HSPs are molecular chaperones involved in numerous cellular processes including protein
folding, transport, assembly and peptide trafficking in antigen presentation. Most HSPs are
expressed constitutively in all cells during normal growth conditions, but their expression is
upregulated under environmental stressors that are unfavourable for protein folding and asso-
ciation [5]. The use of HSPs for vaccination is based on studies in humans and other animal
models showing that immunisation with HSPs elicits potent anti-tumour effects [6–8]. The
immunogenicity of HSPs relates to their capacity to carry antigenic peptides from the tumour
cells from which the HSPs were isolated [9]. The response is mediated by antigen presenting
cells (APCs) that take up the HSP-peptide complexes and present the antigenic peptides to
CD8+ and CD4+ T cells [10]. The interaction of HSP–peptide complexes with APC receptors
also induces innate immune responses. These responses include the maturation of dendritic
cells and the release of cytokines and chemokines by APC and T cells [11].
In the clinical setting, the use of autologous tumour-derived HSPs as an anti-cancer vaccine
has been widely studied. HSP-peptide complexes (HSPPC) can be purified from solid tumours
and have been safely tested in a variety of cancer patients. Thus, HSPs derived from tumours
can be used as tumour-specific vaccines. Members of the HSP90 family have been particularly
used for this approach. Phase I, II and III trials of autologous HSPPC-gp96 vaccination in
human melanoma, renal carcinoma, glioblastoma and colon carcinoma have demonstrated
that immunisation elicits tumour-specific immune responses. No relevant toxicity has been
observed. Overall survival and disease-free survival has improved in some patients with an
immune response. [12–16]. In an alternative approach, the use of HSPs alone (i.e. peptide-
independent) has an immunomodulatory activity within the tumour microenvironment. This
is because HSPs function as adjuvants that enhance innate and adaptive immune responses.
HSPs can move to the extracellular space in soluble form or within exosomes and bind to spe-
cific receptors in a number of cells including natural killer (NK) cells, dendritic cells (DC)
macrophages, peripheral blood monocytes, and B cells [17, 18]. Therefore, HSPs induce
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expression of costimulatory molecules, maturation of DC, secretion of proinflammatory cyto-
kines and activation and migration of NK cells [19–21]. Due to these immunomodulatory
activities, HSP70 has been used as a treatment to enhance specific anti-tumour immune
responses. In preclinical studies and clinical trials involving brain tumours, hepatocellular car-
cinoma, colon or lung cancers, intratumoural injection of HSP70, upregulation of HSP70
within the tumour or the use of selective HSP70 peptides for ex vivo stimulation of immune
cells, stimulated potent anti-tumour immune responses [22–25].
HSPs have not been studied in the Tasmanian devil. Consequently, this study presents the
first characterisation of HSPs in this marsupial and evaluates the suitability of these proteins as
components for the enhancement of a DFTD vaccine. Initially, we used quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR) and protein immunoblot to examine the
expression of a selected range of HSPs in in normal Tasmanian devil tissue, primary DFTD
tumours and DFTD cell lines. We also used these techniques to investigate the occurrence of
inducible HSPs in DFTD cells in vitro, by exposing the cells to environmental stressors such as
heat shock and radiation. Finally, we used an immunoproteomic approach to investigate
whether circulating antibodies against HSPs were present in the serum of devils previously
immunised with whole-DFTD cell vaccine preparations.
Materials and methods
Tissue samples and cell lines
This study was carried out in strict accordance with the recommendations in the University of
Tasmania guidelines. All animal procedures were approved by the University of Tasmania
Animal Ethics Committee under A009215, A0012513 and A0014976. Tasmanian devil tissue
samples and primary DFTD tumours were supplied by the Mount Pleasant Laboratories from
the Tasmanian Department of Primary Industries, Parks, Water and Environment (DPIPWE).
For this study, we used samples from three DFTD primary tumours (TD1- TD592, -TD2-
TD284 and TD3- TD285 and) and skin tissue samples from three animals (TD502, TD518 and
TD579). DFT1 cell lines were provided by A.-M. Pearse and K. Swift of the DPIPWE. These
cell lines were previously established from DFT1 biopsies obtained under research authorities
33/2004-2005 and 24/2006-2008 issued by the Animal Ethics Committee of the DPIWE [26].
Three DFTD cells lines were used: strain 2 (1426), strain 3 (C5065) and strain 4 (4906). The
cell lines were cultured in RPMI culture medium (Thermo Fisher Scientific, Waltham, USA)
containing 10% foetal calf serum (GIBCO, New York, USA), 1% GlutaMAXTM (GIBCO, New
York, USA) and 1% Antibiotic Antimycotic (GIBCO, New York, USA) (complete culture
medium) and kept at 35 oC, 5% CO2 in a humidified incubator.
RNA extraction and quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR)
Tissue samples were homogenised in TriReagent (Sigma-Aldrich, St Louis, USA) with a Mini
Beadbeater-24 (BioSpec Products,Bartlesville, USA) and 2.0 mm Zirconia Beads (BioSpec
Products, Bartlesville, USA). Cell lines were lysed in TriReagent without homogenisation.
RNA extraction and cDNA preparation was performed as previously described [27]. Primer
sequences were designed for target genes identified in the Tasmanian devil reference genome
Devil7.0 assembly GCA_000189315.1, using the NCBI and Ensembl PrimerBLAST tool (S1
Table). Primers were synthesised by GeneWorks (Adelaide, Australia). qRT-PCR was per-
formed using the LightCycler1 480 (Roche, Indianapolis, USA) as previously described [27].
Expression of ribosomal protein 18 (RPS18) was used as reference gene. All analyses included
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no-template controls and no-RT controls. Reaction efficiency was validated using standard
curves, and the comparative Ct method was used for calculation of expression fold change
[28]. Statistical significance was calculated from log2-converted values using a repeated mea-
sures one-way ANOVA and a Dunnett’s multiple comparisons test. GraphPad Prism Version
6.07 was used for statistical analysis and to generate the graphs. Statistical significance relative
to the untreated control is reported as multiplicity adjusted P value:  p<0.05,  p<0.01 and
 p<0.001.
Protein extraction and western blot
Total cell protein from DFTD cell lines was extracted with 1 ml of RIPA buffer (Thermo Scien-
tific, Rockford, IL) containing 10 μl of HALT™ protease inhibitor cocktail (Thermo Scientific,
Rock-ford, USA) for approximately 40 mg of wet cell pellet. The suspension was sonicated three
times for 15 seconds with 50% pulse and then centrifuged at 14,000 X g for 15 minutes. The
supernatant was transferred to a new tube for protein quantification using the EZQ1 Protein
Quantitation kit (Molecular Probes, Eugen, USA) according to the manufacturer’s instructions.
For total protein extraction from devil tissues, samples were homogenised with RIPA buffer
containing protease inhibitors using a Mini Beadbeater-24 (BioSpec Products, Bartlesville,
USA) and 2.0 mm Zirconia Beads (BioSpec Products, Bartlesville, USA). The protein solution
was sonicated, centrifuged and protein quantification determined as indicated above.
For protein electrophoresis 10 μg of protein sample was added to Bolt™ LDS Sample Buffer
(4X) (LifeTechnologies, Carlsbad, USA) and Bolt™ Sample Reducing Agent (10X) with the
remaining volume made up by Milli-Q water to 20 μl. The samples were centrifuged and
heated at 70 oC for 10 min. Samples and a molecular weight marker were loaded on Bolt14–
12% Bis-Tris Plus mini-gels. The gels were run at 165 V constant for 50 min using Bolt™ MES
SDS running buffer and the Bolt1 mini gel tank. The iBlot1 and iBind™ Western Blotting
systems were used for protein electroblotting to nitrocellulose (20 V for 7.5 min) and subse-
quent detection according to the manufacturer’s instructions (Life Technologies, Carlsbad,
USA). Total incubation time with primary and secondary antibodies (S2 Table) was 3 hours.
Immobilon™ Western HRP substrate (Merck Millipore, Billerica, USA) was used for enhanced
chemiluminescent (ECL) detection for 5 minutes followed by imaging using an Amersham™
Imager 600.
Protein expression levels were assessed using the densitometry data acquired from the
images of the western blots. A loading amount of 10 μg of total protein was determined to be
optimal for detecting changes in protein expression for each of the antibodies used (see S1
Fig). Each sample was run in duplicate. A second gel was run in parallel to determine total pro-
tein using SYPRO1 Ruby Protein Gel Stain (Life Technologies, Eugen, USA) following the
manufacturer’s instructions. Fluorescent images were taken using the Amersham™ Imager
600. ImageQuant TL 8.1 software was used for densitometry analysis of the fluorescent gels
and chemiluminescent blots. Background subtraction was determined using the rolling ball
tool and automatic detection of band edges. We use total protein as a loading control. Thus,
the band density of each sample in the chemiluminescent blot was normalised against the den-
sity of the total protein (whole lane) in the fluorescent gel. Images of the blots and the band
analysis are shown in S2 Fig. Final protein expression for each sample was calculated relative
to the control (untreated) sample. Statistical significance was calculated using a one-way
ANOVA of log transformed differential expression data. GraphPad Prism Version 6.07 was
used for statistical analysis and to generate the graphs. Statistical significance relative to the
untreated control is reported as multiplicity adjusted P value:  p<0.05,  p<0.01 and 
p<0.001.
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Heat shock treatment
C5065 DFTD cells were plated at 2x105 cells/well in 6 well trays and grown overnight in com-
plete culture medium. Duplicate trays were placed in a 42˚C water bath for 30 minutes then
returned to the 35˚C incubator. Samples were collected for RNA and protein extraction at 0, 4,
8 and 24 hours post heat shock. For statistical analysis, the duplicates were treated as multiple
observations of the same test condition.
For cell viability analyses after heat shock, C5065 DFTD cells were treated as indicated
above at 35˚C, 42˚C or 45˚C for 30, 60 or 120 minutes. In a separate experiment, the cells were
treated under the same conditions but allowed to recover for 24 hours under normal culture
conditions in a humidified incubator at 35 oC. After the treatments, the cells were harvested
from the wells, washed twice in washing buffer (PBS buffer containing 0.5% bovine serum
albumin and 0.02% sodium azide) and resuspended in 350 μl of washing buffer plus 2 μg/ml
propidium iodide (Sigma-Aldrich, Saint Louis, USA). Cell viability was evaluated by flow
cytometry using a CyAn flow cytometer (Beckman Coulter, Brea, USA). The gating strategy
used for discriminating and quantifying viable and non-viable cells is shown in S3 Fig.
Radiation treatment
C5065 DFTD cells were suspended in complete culture medium and placed in 1.8 ml cryovials
and irradiated with 20 Gy of gamma radiation using a Varian Clinac 23-EX linear accelerator–
Varian Medical Systems Inc. Post irradiation cells were returned to normal culture conditions
at 35˚C for 24 hours before samples were collected for RNA and protein extraction. Control
cells remained untreated at 35˚C in the incubator.
Immunoproteome approach to study tumour antigens
Two-dimensional electrophoresis (2DE). 2DE was performed using the ZOOM1
IPGRunner™ System and the Xcell SureLock™ mini cell (Invitrogen, Carlsbad, USA) following
the instructions of the manufacturer. A summary of the protocol is presented here:
Sample preparation: A 950 μl aliquot of chilled lysis buffer containing ZOOM1 2D protein
solubilizer (Invitrogen, Carlsbad, USA), 1 M tris-base, HALT™ protease inhibitor cocktail and
2 M DTT (Invitrogen, Carlsbad, USA), was added to 50 μl of pelleted C5065 DFTD cells and
the sample sonicated. The lysate was then alkylated with N,N-dimethylacrylamide (DMA)
(Sigma-Aldrich, St Louis, USA) and excess DMA quenched with 2 M DTT, centrifuged, and
the supernatant transferred to a new microcentrifuge tube. A 12 μl aliquot of the lysate con-
taining approximately 15 μg of protein was diluted with sample rehydration buffer containing
1X ZOOM1 2D protein solubilizer, 2 M DTT, ZOOM1 carrier ampholytes (Invitrogen,
Carlsbad, USA) and bromophenol blue.
First dimension—isoelectric focusing (IEF): 155 μl of the protein in sample rehydration
buffer was used to rehydrate each ZOOM1 strip pH 3-10NL overnight using the ZOOM1
IPGRunner™ cassettes (Invitrogen, Carlsbad, USA). After rehydration, isoelectric focusing was
performed using the ZOOM1 IPGRunner™ and the XCell SureLock™ mini-cell. Electrofocus-
ing conditions were 200 V for 20 minutes, 450 V for 15 minutes, 750 V for 15 minutes and
finally 2,000 V for 4 hours.
Second dimension—SDS-PAGE: IEF strips were equilibrated with NuPAGE1 LDS sample
buffer and NuPAGE1 sample reducing agent and then alkylated with alkylation solution con-
taining NuPAGE1 LDS sample buffer and iodoacetamide (Biorad, Hercules, USA). The
equilibrated strips were then applied to second dimension gels (Nu NuPAGE1 Novex1
4–12% Bis-Tris ZOOM1 gels) for SDS-PAGE at 200 V for 40–50 minutes using the
NuPAGE1 XCell SureLock™ mini cell system (Invitrogen, Carlsbad, CA).
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Protein Transfer and immunodetection: The iBlot1 dry blotting system was used for pro-
tein electroblotting of proteins to nitrocellulose membranes at 20 V for 7.5 minutes. Mem-
branes were incubated with pre-immune or immune Tasmanian devil serum [2] at a dilution
of 1:2000 in TBS buffer containing 0.1% tween 20 and 5% skim milk (TBSTM). After four
washes with TBST, the membranes were incubated with a secondary polyclonal rabbit anti-
devil immunoglobulin [29] at a dilution of 1:7500 in TBSTM. The membrane was finally incu-
bated with a donkey horseradish peroxidase (HRP)-conjugated anti-rabbit IgG tertiary anti-
body (Amersham Biosciences, Piscataway, NJ) at a dilution of 1:5000 in TBSTM. A negative
control omitting the primary antibody (devil’s serum) was also run. Chemiluminescent detec-
tion was performed with Immobilon™ Western HRP substrate (Merck Millipore, Billerica,
USA) for 5 minutes and imaged using a Chemi-Smart 5000 digital camera (Vilber Lourmat,
EEC).
Mass spectrometry analysis and selection of proteins. In-gel digestion: 2DE gels were
stained with GelCode™ Blue Safe Protein Stain (Thermo Scientific, Rockford, USA) according
to the manufacturer’s instructions. Matched immunospots were identified in the gel, excised
with a scalpel and transferred to microcentrifuge tubes. Destaining of the spots and in-gel pro-
tein digestion with trypsin was performed using the In-Gel Tryptic Digestion Kit according to
manufacturer’s guidelines (Thermo Scientific, Rockford, USA).
Mass spectrometry and protein identification: Peptide samples were analysed using an
LTQ-Orbitrap tandem mass spectrometer and Surveyor MS Pump Plus (ThermoFisher Scien-
tific, San Jose, CA), using the methodology for peptide separation and detection as previously
described [30]. Briefly, peptides were separated using a 10 cm PicoFrit analytical nanoHPLC
column packed with 5 μm C18 media (New Objective) over a 90 minute step gradient from
100% buffer A (5% acetonitrile in water containing 0.1% formic acid) to 100% buffer B (90%
acetonitrile in water containing 0.1% formic acid). The LTQ-Orbitrap was controlled using
Xcalibur 2.1 software in data-dependent mode and MS/MS spectra were acquired using a
Top8 method with 30-second dynamic exclusion of fragmented peptides.
RAW mass spectrometry files were processed using MaxQuant version 1.5.1.2 (http://
maxquant.org/) without using the ‘match between runs’ function and MS/MS spectra were
searched against the Sarcophilus harrisii UniProt reference proteome (UP000007648; updated
on 11/02/2016) using the Andromeda search engine. Settings for protein identification by
LTQ-Orbitrap MS/MS allowed for a maximum of two missed trypsin cleavages, variable
methionine oxidation, fixed carbamidomethylation and mass error tolerances of 20 ppm then
4.5 ppm for initial and main peptide searches, respectively, and 0.5 Da tolerance for fragment
ions. A 1% false discovery rate was used for peptide-spectrum matches and protein identifica-
tion. Where multiple proteins were reported (e.g. tubulin isoforms) peptides were assigned to
satisfy the principal of parsimony.
Results
1. Patterns of HSP expression in Tasmanian devil skin, primary tumours
and DFTD cell lines
To study the expression of HSPs in the Tasmanian devil, we selected a range of genes belong-
ing to the major HSP families that are annotated in the Tasmanian devil reference genome
(Devil7.0 assembly GCA_000189315.1) (Table 1). We use quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR) to determine the expression of these genes in normal
tissue (skin), primary DFTD tumours and three DFTD cell lines. We found that most of the
HSPs tested were expressed at various levels across all biological replicates (Fig 1). We were
unable to detect basal expression of HSPB1 (HSP27) and have not included this gene in the
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figure. Primary tumours and skin showed similar base line levels of HSP expression. In com-
parison, HSP90B1 (GP96), HSP90AB1 and HSPD1 (HSP60) were expressed at significantly
higher levels in tumour cell lines than skin. HSP90B1 and HSPD1 were also expressed at higher
levels in cell lines than primary tumours. In contrast, HSPA1L (HSP70-1L) was expressed at
higher levels in skin than primary tumours and cell lines. These results confirm that a range of
HSP genes are active in the Tasmanian devil and DFTD.
We then investigated the expression of HSPs at the protein level in three DFTD cell lines
and three primary DFTD tumours using western blotting. We used commercially available
antibodies that showed species cross reactivity with the Tasmanian devil. We used an anti-
HSP70 antibody that detects different members of the HSP70 family; an anti-HSP90 antibody
that detects members of the HSP90 alpha and beta families; an anti-HSP60 that detects
HPSPD1, and an anti GRP94 that detects HSP90B1. We found HSP70, HSP90B1 (GP96),
HSP90 and HSPD1 (HSP60) protein expression in both primary tumours and cell lines (Fig
2). The band intensity observed in the western blots suggested that levels of HSP90B1 and
HSP60 protein expression are higher in cell lines than primary tumours, which correlates with
the levels of expression detected at the mRNA level for these two genes.
Finally, we interrogated a DFTD cellular proteome that we recently acquired using shotgun
proteomic analysis of the C5065 cell line [31] to confirm the presence of heat shock proteins in
the tumour cells. This dataset comprised >1,000 proteins identified on the basis of two or
more unique matching peptides and included 23 HSPs across four families: the HSP70
Table 1. Selected study heat shock protein (HSP) genes annotated in the Tasmanian devil reference genome.
Gene
symbol
Name Other names Description
HSP70 superfamily
HSPA1L Heat shock protein family A
(Hsp70) member 1 like
HSP70-1L This protein stabilizes existing proteins against aggregation and mediates the folding of newly
translated proteins in the cytosol and in organelles.
HSPA2 Heat shock protein family A
(Hsp70) member 2
HSP70-2, HSP70-3 This protein plays a pivotal role in the protein quality control system, ensuring the correct
folding of proteins, the re-folding of misfolded proteins and controlling the targeting of proteins
for subsequent degradation.
HSPA4L Heat shock protein family A
(Hsp70) member 4 like.
HSPH3,
HSP70A4L
Heat shock inducible protein and may act as a chaperone. This protein can protect the heat-
shocked cell against the harmful effects of aggregated proteins.
HSPB family (small heat shock proteins)
HSPB1 Heat shock protein family B
(small) member 1
HSP27, Hsp25 This protein is induced by environmental stress and developmental changes. The protein is
involved in stress resistance and actin organization.
HSP90
family
HSP90AA1 Heat shock protein 90 alpha
family class A member 1
HSP90A, HSPC1,
HSPCA
This protein is an inducible molecular chaperone. The protein aids in the proper folding of
specific target proteins by use of an ATPase activity that is modulated by co-chaperones.
HSP90AB1 Heat shock protein 90 alpha
family class B member 1
HSP90B, HSPC3 Molecular chaperone that promotes the maturation, structural maintenance and proper
regulation of specific target proteins. It is the constitutive form of the cytosolic 90 kDa heat-
shock protein. Undergoes a functional cycle that is linked to its ATPase activity.




Member of a family of adenosine triphosphate (ATP)-metabolizing molecular chaperones with
roles in stabilizing and folding other proteins. The protein is localized to melanosomes and the
endoplasmic reticulum. Expression of this protein is associated with a variety of pathogenic
states, including tumour formation.
Chaperonins family
HSPD1 Heat shock protein family D
(Hsp60) member 1
HSP60 Mitochondrial protein that may function as a signalling molecule of the innate immune system.
It is essential for the folding and assembly of newly imported proteins in the mitochondria.
Nomenclature according to the HUGO Gene Nomenclature Committee (HGNC).
 Description provided by NCBI and UniProt.
https://doi.org/10.1371/journal.pone.0196469.t001
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superfamily (6 proteins); the HSP90 family (3 proteins), the chaperonins (9 proteins) and the
DNAJ/HSP40 family (5 proteins) (S3 Table).
2. HSP expression after heat shock treatment
Several studies have indicated that changes in the expression of HSPs in response to heat
shock treatment increases the immunogenicity of cancer cells (reviewed in [11]). Consequently
we investigated whether the expression of HSPs in DFTD cells was upregulated by heat
Fig 1. Expression of selected HSPs genes at basal level in normal Tasmanian devil skin, primary DFTD tumours and DFTD cell lines.
Expression of the HSPS genes HSPA1L, HSPA2, HSPA4L, HSP90B1,HSPAA1, HSP90AB1,HSPD1, and HSPB1 was analysed using qRT-PCR.
Expression was measured relative to the control gene RPS18. Results are the mean and standard error of three biological replicates. Significance is
defined as  p<0.05,  p<0.01 and  p<0.001. No-cDNA controls and no-RT controls were also included and did not show any amplification of
product. Expression of HSPB1 was not detected at basal level therefore, the figure is not shown. Results are representative of two experiments.
https://doi.org/10.1371/journal.pone.0196469.g001
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treatment. We initially determined the best conditions of heat shock treatment for the DFTD
cell line C5065 (i.e. temperature, time of exposure and cell viability after the treatment) based
on a protocol previously used in a human melanoma cell line [32]. As our DFTD cell cultures
are maintained at 35 oC, cells were treated with this temperature as a control. Cell viability,
measured by flow cytometry, was not affected by heating the cultures at 42 oC for 30 or 60 min-
utes, but was reduced to approximately 40% after 2 hours of treatment. In comparison, heat
treatment at 45 oC reduced the cell viability to less than 10% after the first 30 minutes of treat-
ment (Fig 3A). We also examined cell viability after allowing the heat-treated cultures to
recover under normal conditions (i.e. 35 oC) for 24 hours (Fig 3B). Viability of the recovered
cells that were treated at 42 oC for 30 minutes was similar to the control. However, the viability
of recovered cultures treated at 42 oC for 60 and 120 minutes was reduced. Viability of cultures
treated at 45 oC after 24 hours recovery was lower than 10% of the control. From these experi-
ments we selected 42 oC for 30 minutes as the preferred treatment to study the effects of heat
shock in the expression of HSPs in DFTD cells.
DFTD cells were heat treated as indicated above and HSP expression was determined by
qRT-PCR after different lengths of recovery (0, 4, 8 and 24 hours). Expression of HSPA1L
(HSP70-1L), HSPB1 (HSP27) and HSPAA1 (HSP90A) was significantly increased after heat
treatment (Fig 4A). While upregulation of HSPA1L and HSPB1 was detected immediately after
the treatment, significant upregulation of HSP9AA1was only detected 4 hours after the treat-
ment. Upregulation of the three genes was transient and expression of the HSPs returned to
similar levels as the untreated control after 24 hours of recovery at 35 oC. These results confirm
the presence of at least three heat-inducible genes belonging to the HSP70 and HSP90 super-
families (HSPA1L and HSPAA1, respectively) and the small heat shock protein family (HSPB1)
in Tasmanian devils.
We also used western blot to study changes to the levels of protein expression in DFTD
cells after heat treatment. Significant upregulation of HSP70 was observed at 4 and 8 hours
after treatment (Fig 4B). HSPD1 (HSP60) was significantly upregulated immediately after heat
Fig 2. Expression of selected HSP proteins at basal level in DFTD cell lines and DFTD primary tumours. HSPs
expression was detected by western blot using total protein isolated from three DFTD cell lines (C5065, 1426 and 4946)
and three primary DFTD tumour biopsies (TD1, TD2 and TD3). The anti-HSP70 antibody detects different members
of the HSP70 family; the anti GRP94 antibody detects the HSP90B1, the anti-HSP90 antibody detects various members
of the HSP90 family and the anti-HSP60 detects the HSPD1. Bands represent two technical replicates for each
biological sample. Bands from the same blot in the HSP90 panel were reorganised (vertical black lines) to have a
consistent order in the figure. Original images of the blots are presented in S4 Fig. Results are representative of two
experiments.
https://doi.org/10.1371/journal.pone.0196469.g002
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treatment and was maintained at a heightened level for the 24 hours of recovery time. The
level of protein expression of HSP90 increased after the treatment and was significantly higher
than the control after 8 hours of recovery. Increased HSP90B1 protein expression was
observed only at 24 and was not statistically significant.
3. HSP expression after radiation exposure
Similar to other environmental stressors, radiation may increase the immunogenicity of cancer
cells by upregulating the expression of HSPs [33–35] and by increasing antigen presentation
[36, 37]. As we use radiation to inactivate DFTD cells for our vaccines [2, 3], we were inter-
ested in studying the effects of radiation on the tumour cells. We used qRT-PCR to investigate
the expression of HSPs, calreticulin (CALR) (an “eat me signal” molecule expressed in the sur-
face of cancer cells that promotes their removal by cells of the immune system), B2M and
SAHAI-01, a classical MHC-I molecule of the Tasmanian devil [1, 38]. Of the eight HSPs ana-
lysed, significant changes were only observed in the expression of HSPA1A (HSP70-1a), which
was upregulated, and HSPAA1 (HSP90A), which was downregulated (Fig 5A). CALR and B2M
were also significantly upregulated after radiation. At the protein level, we observed reduced
expression of the HSP70 and HSPD1 (HSP60) after radiation, however, these changes were
not statistically significant (Fig 5B).
4. HSPs as DFTD tumour associated antigens
Immunisation trials with non-viable DFTD cell lines by our research group have shown that
Tasmanian devils can induce humoral responses against DFTD cells [2, 3]. We sought to iden-
tify the DFTD tumour antigens responsible for the antibody response and to investigate
whether circulating antibodies against HSPs were present in the serum of the immunised dev-
ils. To achieve this, we used an immmunoproteomic approach based on separation of DFTD
cellular protein extracts by 2-DE, protein transfer onto nitrocellulose membrane and detection
using serum from immunised devils (primary antibody). Antigen-antibody reactions are then
detected using a polyclonal anti devil immunoglobulin (secondary antibody) and a HRP-
Fig 3. Studies of DFTD cell viability after heat shock treatment. a. DFTD cells growing in culture were exposed to heat shock (42 oC and 45 oC) or
control temperature (35 oC) in a water bath for 30, 60 or 120 min. Cell viability was analysed immediately after the treatment by flow cytometry. Each
marker represents the mean and standard error of three biological replicates. b. DFTD cells in culture were treated as before but returned to normal
incubation conditions (35 oC) to allow recovery for 24 hours. Viability was then measured with flow cytometry. Bars represent the mean and standard
error of three biological replicates. Experiments were repeated twice with reproducible results.
https://doi.org/10.1371/journal.pone.0196469.g003
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conjugated tertiary antibody. Corresponding protein spots of interest are excised from a coo-
massie blue-stained gel run in parallel and, after in-gel trypsin digestion, identified by mass
spectrometry.
We repeated this analysis using the serum collected from two different immunised devils
and the results presented here are representative. Total DFTD protein extracted from a cell
line was separated by 2-DE in four gels run in parallel. Protein from three gels was transferred
to nitrocellulose membranes. One membrane was used as a negative control (no serum con-
trol), the second membrane probed against pre-immune devil serum, and the third membrane
probed with devil serum after immunisation (Fig 6). The western blots revealed a range of
Fig 4. Expression of HSPs after heat shock treatment. Cultured DFTD cells were heat shocked at 42 oC for 30 min in a water bath and then recovered in an incubator
under normal cell culture conditions (35 oC) for 4, 8, or 24 hours. a. HSP gene expression was analysed using qRT-PCR. Expression was measured relative to the control
gene RPS18. Results are the mean and standard error of three biological replicates. Significance is defined as  p<0.05,  p<0.01 and  p<0.001. b. Protein expression
of HSPs was analysed using western blot. Expression was measured relative to the untreated control. Results are the mean and standard error of two biological replicates.
Statistical significance is defined as  p<0.05,  p<0.01 and  p<0.001. Results are representative of two experiments.
https://doi.org/10.1371/journal.pone.0196469.g004
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Fig 5. HSP expression after radiation. Cultured DFTD cells were exposed to gamma radiation (20 Gy) and then recovered for 24 hours in an
incubator under normal cell culture conditions. a. HSP gene expression was analysed using qRT-PCR. Expression was measured relative to the
control gene RPS18. Results are the mean and standard error of three biological replicates. Significance is defined as  p<0.05,  p<0.01 and 
p<0.001. b. Protein expression of HSPs was analysed using western blot. Expression was measured relative to the untreated control. Results are the
mean and standard error of two biological replicates. The results from one single experiment are shown. Statistical significance is defined as 
p<0.05,  p<0.01 and p<0.001.
https://doi.org/10.1371/journal.pone.0196469.g005
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antigens only recognised by antibodies in the immune serum, this is, different from the back-
ground detected in the no-serum control (spots 2 and 19) or by the pre-immune serum (spot
3). All the 19 spots were identified and excised from the fourth 2-D gel and analysed by mass
Fig 6. Screening of antibodies against DFTD tumour antigens using serum from an immunised Tasmanian devil.
Total cell proteins from cultured DFTD cells were separated by two-dimensional gel-electrophoresis, transferred to
nitrocellulose membrane and probed with pre-immune serum or post-immunisation serum. Negative control (no
serum) is also shown. Arrows indicate spots detected by the immune serum that were selected for further identification
by mass spectrometry (see Table 2). Experiments were repeated twice with reproducible results.
https://doi.org/10.1371/journal.pone.0196469.g006
Table 2. DFTD tumour antigens recognised by serum of an immunised Tasmanian devil and identified by mass spectrometry.
Spot Unique peptides Amino acid coverage (%) Mass (kDa) Accession number Gene symbol Protein name
7,8,9 6 41.9 28 G3WCJ6 YWHAB 14-3-3 protein beta/alpha
7,8,9 7 39.9 29 G3WP04 YWHAE 14-3-3 protein epsilon
7,8,9 2 21.7 28 G3VE53 YWHAH 14-3-3 protein eta
7,8,9 5 34 28 G3VS43 YWHAQ 14-3-3 protein theta
7,8,9,10 11 54.7 28 G3WHE0 YWHAZ 14-3-3 protein zeta/delta
1 11 31.1 61 G3WZS7 HSPD1 60 kDa heat shock protein, mitochondrial
19 4 6.2 87 G3W8J9 ACO2 Aconitase hydratase, mitochondrial
10 2 12.3 24 G3W6S0 NUDT5 ADP-sugar pyrophosphatase
2,4,18 20 54.9 55 G3VIJ8 ATP5B ATP synthase subunit beta, mitochondrial
12 4 14 37 G3W5Z0 CTSB Cathepsin B
11 7 54.4 15 G3WZD1 CRABP1 Cellular retinoic acid-binding protein 1
19 3 6.1 80 G3WXK9 APPL1 DCC-interacting protein 13-alpha
2,4,5,6,18 2 6.6 53 G3WHB8 DES Desmin
19 11 23.2 82 G3X0B8 GSN Gelsolin
19 4 7.2 83 G3WYP8 HSP90AB1 Heat shock protein HSP 90-beta
1,2 5 16.5 51 G3WXL4 HNRNPK Heterogeneous nuclear ribonucleoprotein K
14,15,16,17 3 27.8 13 G3VNV7 LOC100928127 Histone H2B
18 11 32.9 53 G3VGI4 PLIN3 Perilipin-3
17 3 21.4 22 G3VCM9 PRDX5 Peroxiredoxin-5, mitochondrial
7 5 34.9 28 G3WDY3 PCNA Proliferating cell nuclear antigen
3 8 17.3 57 G3WBV2 P4HB Protein disulfide-isomerase
10 6 41.2 23 G3WB53 ARHGDIA Rho GDP dissociation inhibitor 1
16 4 23.3 17 G3VVY5 STMN1 Stathmin
17 3 23.1 15 G3VNM4 SOD1 Superoxide dismutase [Cu-Zn]
12 2 10.3 32 G3VNJ4 TMX1 Thioredoxin-related transmembrane protein 1
11 2 18.1 12 G3VX55 TXN Thioredoxin
7 4 17.6 28 G3VU66 TPM4 Tropomyosin alpha-4 chain
2,4,16,18 2 33 50 G3WSM9 LOC100920562 Tubulin alpha chain
2,4,18 2 38.6 50 G3VPL9 TUBA1C Tubulin alpha-1C chain
2,4,18 14 34.1 50 G3WFK2 TUBA8 Tubulin alpha-8 chain
4,18 5 42.3 50 G3W109 TUBB Tubulin beta chain
4,18 2 35.5 50 G3WMM3 TUBB2A Tubulin beta-2A chain
4,18 17 45.4 50 G3WJU5 TUBB4A Tubulin beta-4A chain
4,18 6 40.6 50 G3VXT3 TUBB6 Tubulin beta-6 chain
13 2 12.7 25 G3WV76 UCHL1 Ubiquitin carboxyl-terminal hydrolase isozyme L1
18 6 22.2 45 G3WRR2 UBA5 Ubiquitin-like modifier-activating enzyme 5
1,2,3,4.5,6,18 25 77.2 53 G3WPL8 VIM Vimentin
 Gene and protein names according to The Universal Protein Resource (UniProt).
https://doi.org/10.1371/journal.pone.0196469.t002
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spectrometry, resulting in the identification of 27 different proteins. In some cases, several iso-
forms of a single protein were detected. In this case, all isoforms were collectively counted as a
one protein (Table 2 and S4 Table). Literature searching using PubMed found that many of
the proteins had been previously identified as tumour antigens or were associated with the
immune response to cancer in other species. In particular, 11 proteins were found to have
well-documented information for their relation to cancer, including the HSP60 proteins (S5
Table). These preliminary results indicate that it is feasible to use immunoproteomics to iden-
tify DFTD-associated antigens. Furthermore, this preliminary study shows that HSP60 pro-
teins are antigenic and may contribute to the humoral response observed in our vaccination
trials.
Discussion
In this study we present the first characterisation of heat shock proteins (HSPs) in the marsu-
pial Tasmanian devil. We evaluated the suitability of these proteins as antigenic components
of a vaccine against devil facial tumour disease (DFTD). Our results confirmed the constitutive
expression of a wide range of HSPs in normal devil tissue, primary DFTD tumours and DFTD
cell lines. We also confirmed the expression of stress-inducible HSPs in DFTD cancer cells.
More importantly, antibodies present in the serum of immunised devils recognised a range of
DFTD proteins including HSPs. These results support the feasibility of using HSPs prepara-
tions as components for the enhancement of a DFTD vaccine.
HSPs are considered one of the most phylogenetically conserved group of proteins [4]. In
normal cells, HSPs play essential roles in the synthesis, transport and folding of proteins. In
cancer cells, HSPs are also important regulators of cellular responses and functions during car-
cinogenesis [39]. Therefore, it was not surprising that basal HSP expression was detected both
in the skin of the Tasmanian devil and in DFTD tumour cells. We confirmed expression of
members of several HSP families described in the literature [40]. These included the HSP70
superfamily (HSPA and HSPH families), the HSPB family, the HSP90 family, the chaperonin
family and the HSP40 (DNAJ) family.
Compared to normal devil skin, we found significantly higher expression of HSPD1
(HSP60) and two HSP90 proteins (HSP90B1 and HSP90AB1) in cultured DFTD cells. HSP60
and HSP90 are overexpressed in numerous human cancers and have been correlated with can-
cer progression and poor prognosis [41–49]. HSPs promote cancer development through the
regulation of angiogenesis, cell proliferation, migration, invasion and metastases [50]. Addi-
tionally, cancer cells have higher metabolic requirements for chaperones than normal cells in
order to resist stressors such as protein overload and hypoxia. DFTD is an aggressive cancer
and metastases are frequent in affected animals. It is therefore possible that HSP60 and HSP90
exert similar cancer promoting functions in DFTD cells.
An important function of HSPs involves protecting cells from irreversible damage under
stressful conditions that could lead to cell death [51]. In the current study, heat shock upregu-
lated HSPA1L (HSP70-1L), HSPB1 (HSP27), HSPAA1 (HSP90A) and HSPD1 (HSP60), con-
firming that HSPs in DFTD cells are stress responsive. In eukaryotes, this rapid and classical
stress response occurs via transcriptional induction of the heat shock genes via the heat shock
transcription factor (HSF1), which binds highly conserved regulatory sequences (heat shock
elements, HSEs) located within heat shock gene promoters [52]. Interestingly, our study
showed that cancer cells of the marsupial Tasmanian devil upregulate HSPA1L after heat
shock. In mammals, the HSP70 family genes belonging to the HSPA1 cluster include three
genes. Two of these genes, HSP1A and HSPA1B, contain HSEs in their regulatory regions and
their expression is strongly increased in most tissues after heat shock and other stressors. The
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third gene, HSP1AL, is localized in close vicinity to HSPA1A but not contain HSEs in the pro-
moter; in humans this gene is not inducible [53]. Comparative studies of the regulation of the
heat shock promoters in insects and mammals show that the heat shock regulation system is
not universal for distant species, and the variability in the evolution of individual heat shock
genes may depend on environmental conditions. For example, studies in camels, which are
adapted to live in arid desert areas, show that tissues of this species constitutively express all
three members of the HSPA1 cluster under normal physiological conditions. Moreover, the
study showed that heat shock also increases the expression levels of the three members of the
cluster. Although the regulatory mechanisms responsible for the increased level of the expres-
sion of the constitutive HSPA1L (that lacks heat shock elements) are unknown, it was sug-
gested that the genes in the cluster HSPA1 may interact functionally with each other [54]. If
this is the case for the regulation of heat shock expression in the Tasmanian devil and other
marsupials, further investigation is required.
I addition to the regulatory mechanisms present at the transcriptional level, the expression
of HSP is also highly controlled at the post-transcriptional level [55–57]. Our results suggest
the existence of this machinery in DFTD cells. We observed elevated protein expression of
HSP60 immediately after heat treatment but we were unable to detect variation at the mRNA
level. It has been suggested that eukaryotic translation initiation factors (eIF) and other mecha-
nisms influence the translation of HSP after heat shock. Studies in HeLa cells deficient in eIF-
4E and eIF-4γ, detected newly synthetised HSP70 and HSP90 without increase in respective
mRNAs levels. The study suggested that HSPs are translated by cap-independent pathways
[56]. In contrast to our observation, a study using human prostate carcinoma cell lines showed
that despite an increase in HSP60 mRNA after heat shock, no increase in HSP60 protein was
detected [58]. The reason for this discrepancy is not known. It may indicate different regula-
tory mechanisms at the cellular level or perhaps at the species level which defines topics for
future research.
Radiation is another environmental pressure that triggers a cellular stress response with
implications for cancer progression. As a cancer therapy, radiation influences a number of bio-
logical and immunological functions in cancer cells leading to contrasting outcomes. Radia-
tion induces the expression of HSPs that protect cancer cells by inhibiting radiation-induced
apoptosis [59]. On the other hand, radiation induces overexpression of HSP70, HSP90 and cal-
reticulin (CALR), which promotes anti-tumor immunity [34]. Furthermore, radiation may
increase antigen presentation by upregulating MHC-I expression [37]. Our current whole-cell
vaccination approach uses high doses of radiation (two daily doses of 40 Gy each) as a safety
measure to completely inactivate the DFTD cells prior immunisation of Tasmanian devils [3].
In this study, we used a lower radiation level of 20 Gy to study its effect on HSP expression in
DFTD cells. We were not able to detect changes in HSP expression at the mRNA or protein
level after the radiation treatment. These data is in line with others studies indicating that radi-
ation is not a powerful inducer of HSP expression [58]. On the other hand, radiation upregu-
lated the gene expression of B2M and CALR suggesting that this treatment may be used as a
mechanism to increase the immunogenicity of DFTD cells. Several studies have showed that
the translocation of calreticulin to the plasma membrane induced by radiation is critical for
the recognition of dying tumour cells by dendritic cells [36, 60]. Additionally, surface expres-
sion of calreticulin is also correlated with an increased antitumor immune response by natural
killer cells and effector memory CD4+ and CD8+ T cells [61]. The use of lower doses of radia-
tion in combination with mechanical inactivation of the cells (e.g. freezing/thawing) may be a
feasible strategy to increase the immunogenicity of DFTD cells and the efficacy of our current
DFTD vaccine.
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Our study provides preliminary evidence that HSPs in DFTD are immunogenic. In particu-
lar, we identified HSP60 as tumour antigen recognised by the serum from a devil immunised
with DFTD tumour cells. These findings show that immunoproteomics is a viable technique
for characterisation of specific DFTD tumour antigens. Although the results are preliminary,
the antigens identified using this technique may provide clues about tumourigenic processes
occurring in this unique cancer and could be useful for the development of an anti-DFTD vac-
cine. Some of the identified antigens relate to pathways considered “hallmarks of cancer cells”
[62]. Biological processes include: cell cycle progression (14-3-3 proteins), signal transduction
(HSP90 and HSP60), cellular bioenergy (aconitate hydratase and ATP synthase), proliferation
(14-3-3 proteins, cathepsin B, cellular retinoic acid, gelsolin and proliferating cell nuclear anti-
gen), migration (gelsolin and cathepsin B) and apoptosis (14-3-3 proteins, HSP60 and DCC-
interaction protein 13-alpha). Future studies are required to confirm the role and possible
therapeutic applications of these proteins in DFTD.
Taking together, our results support the feasibility of using HSP preparations derived from
DFTD cells as an alternative, or to complement, the current whole-tumour cell formulation.
Several approaches to separate HSPs from tumour cells for use in cancer vaccines have already
been developed and tested. The efficacy of autologous HSP preparation as an immunotherapy
was initially demonstrated by Tamura et al., in 1997 [63]. Their study showed that tumour-
derived GP96 (HSP90B1) and HSP70 preparations were able to eradicate established tumours
in animal models. Moreover, GP96 preparations derived from metastatic lesions were also
effective in conferring long term protection against the primary tumour. The anti-tumour effi-
cacy is derived from the ability of the HSP to chaperone the entire antigenic repertoire of the
cells from which they are isolated. Antigen presenting cells can take up HSP-peptide com-
plexes and present the antigenic peptides to CD8+ and CD4+ T cells [10]. Following these stud-
ies, various clinical trials with cancer patients have been initiated (reviewed in [8, 11]). The
first autologous cancer-derived vaccine based on GP96 is known as Vitespen1 and has shown
promising results in patients with melanoma and kidney cancer (reviewed in [64]). More
recently, HSP peptide complex–96 (HSPPC-96) has been tested in a phase II study of patients
with recurrent glioblastoma multiforme (GBM). The study indicated that the vaccine is safe
and its efficacy encouraging [65]. Similar studies using HSP70-peptide complexes have been
tested in patients with leukemia and other cancers [8, 66].
DFTD cells lack components of the antigen presenting machinery [1], therefore our current
vaccine incorporates DFTD cells treated with cytokines to restore surface MHC-I expression.
A downside to this approach involves the concurrent upregulation of the immune-inhibitory
molecule PD-L1 with MHC-I [67]. In this sense, HSP preparations are advantageous as they
may carry a wide repertoire of antigenic peptides derived from the tumour cells independently
of MHC-I [9]. A constraint of using HSP-peptide complexes for human therapy is the limited
availability of tumour-derived tissue from cancer patients. Conversely, DFTD is a clonal can-
cer, therefore vaccination can include a common batch of HSP preparations that are purified
from readily available cell lines or tumour biopsies. Further research in the development of
HSP-vaccine against DFTD in Tasmanian devils is warranted.
The main objective of this study was to evaluate the potential of using HSPs as an antigenic
substitute to whole tumour cell extracts in DFTD vaccines. Here we have shown that tissues
and cancer cells from the Tasmanian devil express constitutive and stress-inducible HSPs.
More importantly, our study suggests that HSPs derived from DFTD cancer cells are immuno-
genic and are recognised by the devil’s immune system. Taken together, our findings pave the
way for the future development of HSP-based vaccine against DFTD.
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S1 Fig. Titration of antibodies. Optimal amount of protein to load in the gels was determined
for each antibody. Each sample was run in duplicate (four top panels). A second gel was run in
parallel to determine total protein using SYPRO1 Ruby Protein Gel Stain (bottom panels).
ImageQuant TL 8.1 software was used for densitometry analysis of the blots and gels.
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S2 Fig. Band analysis for protein quantitation.
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(PDF)
S2 Table. Antibodies used in the study.
(PDF)
S3 Table. HSPs identified in the proteome of a DFTD cell line.
(PDF)
S4 Table. MaxQuant output txt files.
(XLSX)




The authors would like to thank Andrew McGrath and Tim Williams from the Department of
Radiation Oncology (WP Holman Clinic) at the Royal Hobart Hospital—Tasmania for provid-
ing technical assistance for the radiation of the cell lines. The authors would like to thank Shea
Rolf, Monika Payerhin, Georgia Cox and Luke Prismall for their contributions to the develop-
ment of this work.
Author Contributions
Conceptualization: Cesar Tovar, Gregory M. Woods.
Formal analysis: Cesar Tovar, Amanda L. Patchett, Vitna Kim.
Funding acquisition: Cesar Tovar, A. Bruce Lyons, Gregory M. Woods.
Investigation: Cesar Tovar, Amanda L. Patchett, Vitna Kim, Richard Wilson, Jocelyn Darby.
Methodology: Cesar Tovar, Amanda L. Patchett, Vitna Kim, Richard Wilson, Jocelyn Darby.
Project administration: Cesar Tovar, Gregory M. Woods.
Supervision: Cesar Tovar, A. Bruce Lyons, Gregory M. Woods.
Visualization: Cesar Tovar, Amanda L. Patchett, Vitna Kim, Richard Wilson, Jocelyn Darby.
Expression of heat shock proteins in the marsupial Tasmanian devil
PLOS ONE | https://doi.org/10.1371/journal.pone.0196469 April 27, 2018 18 / 22
Writing – original draft: Cesar Tovar.
Writing – review & editing: Cesar Tovar, Amanda L. Patchett, Vitna Kim, Richard Wilson,
Jocelyn Darby, A. Bruce Lyons, Gregory M. Woods.
References
1. Siddle HV, Kreiss A, Tovar C, Yuen CK, Cheng YY, Belov K, et al. Reversible epigenetic down-regula-
tion of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious can-
cer. Proc Natl Acad Sci U S A. 2013; 110(13):5103–8. https://doi.org/10.1073/pnas.1219920110 PMID:
23479617
2. Kreiss A, Brown GK, Tovar C, Lyons AB, Woods GM. Evidence for induction of humoral and cytotoxic
immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii)
immunized with killed cell preparations. Vaccine. 2015; 33(26):3016–25. https://doi.org/10.1016/j.
vaccine.2015.01.039 PMID: 25708088
3. Tovar C, Pye RJ, Kreiss A, Cheng Y, Brown GK, Darby J, et al. Regression of devil facial tumour dis-
ease following immunotherapy in immunised Tasmanian devils. Scientific reports. 2017; 7:43827.
https://doi.org/10.1038/srep43827 PMID: 28276463
4. Lindquist S, Craig EA. The heat-shock proteins. Annual review of genetics. 1988; 22:631–77. https://
doi.org/10.1146/annurev.ge.22.120188.003215 PMID: 2853609
5. Welch WJ. Heat shock proteins functioning as molecular chaperones: their roles in normal and stressed
cells. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 1993;
339(1289):327–33. https://doi.org/10.1098/rstb.1993.0031 PMID: 8098537
6. Graner M, Raymond A, Akporiaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by
free-solution isoelectric focusing yields potent antitumor vaccines. Cancer immunology, immunother-
apy: CII. 2000; 49(9):476–84. PMID: 11092614
7. Binder RJ. Functions of heat shock proteins in pathways of the innate and adaptive immune system.
Journal of immunology (Baltimore, Md: 1950). 2014; 193(12):5765–71.
8. Ciocca DR, Cayado-Gutierrez N, Maccioni M, Cuello-Carrion FD. Heat shock proteins (HSPs) based
anti-cancer vaccines. Current molecular medicine. 2012; 12(9):1183–97. PMID: 22804241
9. Graner MW, Romanoski A, Katsanis E. The ’peptidome’ of tumour-derived chaperone-rich cell lysate
anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. International
journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology, North
American Hyperthermia Group. 2013; 29(5):380–9.
10. Shinagawa N, Yamazaki K, Tamura Y, Imai A, Kikuchi E, Yokouchi H, et al. Immunotherapy with
dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through
immune response of CD8+ cytotoxic T lymphocytes and natural killer cells. Cancer immunology,
immunotherapy: CII. 2008; 57(2):165–74. https://doi.org/10.1007/s00262-007-0359-3 PMID:
17628800
11. Zhang Y, Zheng L. Tumor immunotherapy based on tumor-derived heat shock proteins (Review).
Oncology letters. 2013; 6(6):1543–9. https://doi.org/10.3892/ol.2013.1616 PMID: 24260044
12. Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, et al. A phase II trial of vaccination with
autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF
and interferon-alpha in metastatic melanoma patients. Cancer immunology, immunotherapy: CII. 2006;
55(8):958–68. https://doi.org/10.1007/s00262-005-0084-8 PMID: 16215718
13. Mazzaferro V, Coppa J, Carrabba MG, Rivoltini L, Schiavo M, Regalia E, et al. Vaccination with autolo-
gous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clini-
cal cancer research: an official journal of the American Association for Cancer Research. 2003; 9
(9):3235–45.
14. Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, et al. Individual patient-specific immunity
against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD
chaperone protein. Clinical cancer research: an official journal of the American Association for Cancer
Research. 2013; 19(1):205–14.
15. Zhang K, Peng Z, Huang X, Qiao Z, Wang X, Wang N, et al. Phase II Trial of Adjuvant Immunotherapy
with Autologous Tumor-derived Gp96 Vaccination in Patients with Gastric Cancer. Journal of Cancer.
2017; 8(10):1826–32. https://doi.org/10.7150/jca.18946 PMID: 28819380
16. Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, et al. Phase III comparison of vite-
spen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s
Expression of heat shock proteins in the marsupial Tasmanian devil
PLOS ONE | https://doi.org/10.1371/journal.pone.0196469 April 27, 2018 19 / 22
choice of treatment for stage IV melanoma: the C-100-21 Study Group. Journal of clinical oncology: offi-
cial journal of the American Society of Clinical Oncology. 2008; 26(6):955–62.
17. Mambula SS, Stevenson MA, Ogawa K, Calderwood SK. Mechanisms for Hsp70 secretion: crossing
membranes without a leader. Methods (San Diego, Calif). 2007; 43(3):168–75.
18. Asea A. Stress proteins and initiation of immune response: chaperokine activity of hsp72. Exercise
immunology review. 2005; 11:34–45. PMID: 16385842
19. Asea A. Initiation of the Immune Response by Extracellular Hsp72: Chaperokine Activity of Hsp72. Cur-
rent immunology reviews. 2006; 2(3):209–15. PMID: 17502920
20. Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, et al. Heat shock protein 70
surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer
research. 2005; 65(12):5238–47. https://doi.org/10.1158/0008-5472.CAN-04-3804 PMID: 15958569
21. Boudesco C, Cause S, Jego G, Garrido C. Hsp70: A Cancer Target Inside and Outside the Cell. Meth-
ods Mol Biol. 2018; 1709:371–96. https://doi.org/10.1007/978-1-4939-7477-1_27 PMID: 29177673
22. Shevtsov M, Multhoff G. Heat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treat-
ment of Cancer. Front Immunol. 2016; 7:171. https://doi.org/10.3389/fimmu.2016.00171 PMID:
27199993
23. Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, et al. Treatment of colon and lung
cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a
clinical phase i trial. Clinical cancer research: an official journal of the American Association for Cancer
Research. 2004; 10(11):3699–707.
24. Specht HM, Ahrens N, Blankenstein C, Duell T, Fietkau R, Gaipl US, et al. Heat Shock Protein 70
(Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell
Lung Cancer (NSCLC) after Radiochemotherapy (RCTx)—From Preclinical Studies to a Clinical Phase
II Trial. Front Immunol. 2015; 6:162. https://doi.org/10.3389/fimmu.2015.00162 PMID: 25926832
25. Shevtsov MA, Kim AV, Samochernych KA, Romanova IV, Margulis BA, Guzhova IV, et al. Pilot study of
intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in
children. OncoTargets and therapy. 2014; 7:1071–81. https://doi.org/10.2147/OTT.S62764 PMID:
24971017
26. Pearse AM, Swift K, Hodson P, Hua B, McCallum H, Pyecroft S, et al. Evolution in a transmissible can-
cer: a study of the chromosomal changes in devil facial tumor (DFT) as it spreads through the wild Tas-
manian devil population. Cancer genetics. 2012; 205(3):101–12. https://doi.org/10.1016/j.cancergen.
2011.12.001 PMID: 22469509
27. Patchett AL, Latham R, Brettingham-Moore KH, Tovar C, Lyons AB, Woods GM. Toll-like receptor sig-
naling is functional in immune cells of the endangered Tasmanian devil. Dev Comp Immunol. 2015; 53
(1):123–33. https://doi.org/10.1016/j.dci.2015.07.003 PMID: 26182986
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR
and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif). 2001; 25(4):402–8.
29. Kreiss A. The immune responses of the Tasmanian devil (Sarcophilus harrisii) and the devil facial
tumour disease. Thesis, University of Tasmania. 2009. Available from: https://login.ezproxy.utas.edu.
au/login?url=. http://search.ebscohost.com/login.aspx?direct=true&db=cat02831a&AN=UTas.
b1523412&site=eds-live http://eprints.utas.edu.au/22449/.
30. Al-Naseri A, Bowman JP, Wilson R, Nilsson RE, Britz ML. Impact of lactose starvation on the physiology
of Lactobacillus casei GCRL163 in the presence or absence of tween 80. Journal of proteome research.
2013; 12(11):5313–22. https://doi.org/10.1021/pr400661g PMID: 24066708
31. Patchett AL, Wilson R, Charlesworth JC, Corcoran LM, Papenfuss AT, Lyons AB, et al. Transcriptome
and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian
devil facial tumor disease (DFTD) cells. Oncotarget. 2018; 9:15895–914. https://doi.org/10.18632/
oncotarget.24634 PMID: 29662615
32. Milani V, Frankenberger B, Heinz O, Brandl A, Ruhland S, Issels RD, et al. Melanoma-associated anti-
gen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock
response. International immunology. 2005; 17(3):257–68. https://doi.org/10.1093/intimm/dxh203
PMID: 15642953
33. Schmid TE, Multhoff G. Radiation-induced stress proteins—the role of heat shock proteins (HSP) in
anti- tumor responses. Current medicinal chemistry. 2012; 19(12):1765–70. PMID: 22414085
34. Multhoff G, Pockley AG, Schmid TE, Schilling D. The role of heat shock protein 70 (Hsp70) in radiation-
induced immunomodulation. Cancer letters. 2015; 368(2):179–84. https://doi.org/10.1016/j.canlet.
2015.02.013 PMID: 25681671
Expression of heat shock proteins in the marsupial Tasmanian devil
PLOS ONE | https://doi.org/10.1371/journal.pone.0196469 April 27, 2018 20 / 22
35. Calini V, Urani C, Camatini M. Overexpression of HSP70 is induced by ionizing radiation in C3H 10T1/2
cells and protects from DNA damage. Toxicology in vitro: an international journal published in associa-
tion with BIBRA. 2003; 17(5–6):561–6.
36. Salimu J, Spary LK, Al-Taei S, Clayton A, Mason MD, Staffurth J, et al. Cross-Presentation of the Onco-
fetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells—A Key Role for Heat-Shock Protein 70
and Receptor CD91. Cancer immunology research. 2015; 3(6):678–88. https://doi.org/10.1158/2326-
6066.CIR-14-0079 PMID: 25678582
37. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modu-
lates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor
immunotherapy. The Journal of experimental medicine. 2006; 203(5):1259–71. https://doi.org/10.1084/
jem.20052494 PMID: 16636135
38. Siddle HV, Sanderson C, Belov K. Characterization of major histocompatibility complex class I and
class II genes from the Tasmanian devil (Sarcophilus harrisii). Immunogenetics. 2007; 59(9):753–60.
https://doi.org/10.1007/s00251-007-0238-2 PMID: 17673996
39. Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S. Heat Shock Proteins and Cancer. Trends in pharmacological
sciences. 2017; 38(3):226–56. https://doi.org/10.1016/j.tips.2016.11.009 PMID: 28012700
40. Kampinga HH, Hageman J, Vos MJ, Kubota H, Tanguay RM, Bruford EA, et al. Guidelines for the
nomenclature of the human heat shock proteins. Cell stress & chaperones. 2009; 14(1):105–11.
41. Giaginis C, Daskalopoulou SS, Vgenopoulou S, Sfiniadakis I, Kouraklis G, Theocharis SE. Heat Shock
Protein-27, -60 and -90 expression in gastric cancer: association with clinicopathological variables and
patient survival. BMC gastroenterology. 2009; 9:14. https://doi.org/10.1186/1471-230X-9-14 PMID:
19203381
42. Hwang YJ, Lee SP, Kim SY, Choi YH, Kim MJ, Lee CH, et al. Expression of heat shock protein 60 kDa
is upregulated in cervical cancer. Yonsei medical journal. 2009; 50(3):399–406. https://doi.org/10.3349/
ymj.2009.50.3.399 PMID: 19568603
43. Hamelin C, Cornut E, Poirier F, Pons S, Beaulieu C, Charrier JP, et al. Identification and verification of
heat shock protein 60 as a potential serum marker for colorectal cancer. The FEBS journal. 2011; 278
(24):4845–59. https://doi.org/10.1111/j.1742-4658.2011.08385.x PMID: 21973086
44. Li XS, Xu Q, Fu XY, Luo WS. Heat shock protein 60 overexpression is associated with the progression
and prognosis in gastric cancer. PLoS One. 2014; 9(9):e107507. https://doi.org/10.1371/journal.pone.
0107507 PMID: 25207654
45. Shi Y, Liu X, Lou J, Han X, Zhang L, Wang Q, et al. Plasma levels of heat shock protein 90 alpha associ-
ated with lung cancer development and treatment responses. Clinical cancer research: an official jour-
nal of the American Association for Cancer Research. 2014; 20(23):6016–22.
46. Patel K, Wen J, Magliocca K, Muller S, Liu Y, Chen ZG, et al. Heat shock protein 90 (HSP90) is overex-
pressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates
the effects of chemoradiation. Cancer chemotherapy and pharmacology. 2014; 74(5):1015–22. https://
doi.org/10.1007/s00280-014-2584-8 PMID: 25205430
47. McCarthy MM, Pick E, Kluger Y, Gould-Rothberg B, Lazova R, Camp RL, et al. HSP90 as a marker of
progression in melanoma. Annals of oncology: official journal of the European Society for Medical
Oncology. 2008; 19(3):590–4.
48. Desmetz C, Bibeau F, Boissiere F, Bellet V, Rouanet P, Maudelonde T, et al. Proteomics-based identifi-
cation of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in
situ. Journal of proteome research. 2008; 7(9):3830–7. https://doi.org/10.1021/pr800130d PMID:
18683965
49. Hjerpe E, Egyhazi S, Carlson J, Stolt MF, Schedvins K, Johansson H, et al. HSP60 predicts survival in
advanced serous ovarian cancer. International journal of gynecological cancer: official journal of the
International Gynecological Cancer Society. 2013; 23(3):448–55.
50. Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausei S, Boni L, et al. The role of heat shock pro-
teins in cancer. Cancer letters. 2015; 360(2):114–8. https://doi.org/10.1016/j.canlet.2015.02.026 PMID:
25721081
51. Morimoto RI. Cells in stress: transcriptional activation of heat shock genes. Science. 1993; 259
(5100):1409–10. PMID: 8451637
52. Wu C. Heat shock transcription factors: structure and regulation. Annual review of cell and developmen-
tal biology. 1995; 11:441–69. https://doi.org/10.1146/annurev.cb.11.110195.002301 PMID: 8689565
53. Hess K, Oliverio R, Nguyen P, Le D, Ellis J, Kdeiss B, et al. Concurrent action of purifying selection and
gene conversion results in extreme conservation of the major stress-inducible Hsp70 genes in mam-
mals. Scientific reports. 2018; 8(1):5082. https://doi.org/10.1038/s41598-018-23508-x PMID:
29572464
Expression of heat shock proteins in the marsupial Tasmanian devil
PLOS ONE | https://doi.org/10.1371/journal.pone.0196469 April 27, 2018 21 / 22
54. Garbuz DG, Astakhova LN, Zatsepina OG, Arkhipova IR, Nudler E, Evgen’ev MB. Functional organiza-
tion of hsp70 cluster in camel (Camelus dromedarius) and other mammals. PLoS One. 2011; 6(11):
e27205. https://doi.org/10.1371/journal.pone.0027205 PMID: 22096537
55. Folgueira C, Quijada L, Soto M, Abanades DR, Alonso C, Requena JM. The translational efficiencies of
the two Leishmania infantum HSP70 mRNAs, differing in their 3’-untranslated regions, are affected by
shifts in the temperature of growth through different mechanisms. The Journal of biological chemistry.
2005; 280(42):35172–83. https://doi.org/10.1074/jbc.M505559200 PMID: 16105831
56. Joshi-Barve S, De Benedetti A, Rhoads RE. Preferential translation of heat shock mRNAs in HeLa cells
deficient in protein synthesis initiation factors eIF-4E and eIF-4 gamma. The Journal of biological chem-
istry. 1992; 267(29):21038–43. PMID: 1400417
57. Baena-Lopez LA, Alonso J, Rodriguez J, Santaren JF. The expression of heat shock protein HSP60A
reveals a dynamic mitochondrial pattern in Drosophila melanogaster embryos. Journal of proteome
research. 2008; 7(7):2780–8. https://doi.org/10.1021/pr800006x PMID: 18549261
58. Tang D, Khaleque MA, Jones EL, Theriault JR, Li C, Wong WH, et al. Expression of heat shock proteins
and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors
in vivo. Cell stress & chaperones. 2005; 10(1):46–58.
59. Lee SJ, Choi SA, Lee KH, Chung HY, Kim TH, Cho CK, et al. Role of inducible heat shock protein 70 in
radiation-induced cell death. Cell stress & chaperones. 2001; 6(3):273–81.
60. Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P, et al. Ecto-calreticulin in immuno-
genic chemotherapy. Immunological reviews. 2007; 220:22–34. https://doi.org/10.1111/j.1600-065X.
2007.00567.x PMID: 17979837
61. Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I, et al. Calreticulin exposure by
malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML
patients. Blood. 2016; 128(26):3113–24. https://doi.org/10.1182/blood-2016-08-731737 PMID:
27802968
62. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646–74. https://
doi.org/10.1016/j.cell.2011.02.013 PMID: 21376230
63. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-
derived heat shock protein preparations. Science. 1997; 278(5335):117–20. PMID: 9311915
64. Randazzo M, Terness P, Opelz G, Kleist C. Active-specific immunotherapy of human cancers with the
heat shock protein Gp96-revisited. International journal of cancer. 2012; 130(10):2219–31. https://doi.
org/10.1002/ijc.27332 PMID: 22052568
65. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, et al. Heat-shock protein peptide complex-96
vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro-oncology. 2014; 16(2):274–9.
https://doi.org/10.1093/neuonc/not203 PMID: 24335700
66. Li Z, Qiao Y, Liu B, Laska EJ, Chakravarthi P, Kulko JM, et al. Combination of imatinib mesylate with
autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clinical cancer
research: an official journal of the American Association for Cancer Research. 2005; 11(12):4460–8.
67. Flies AS, Lyons AB, Corcoran LM, Papenfuss AT, Murphy JM, Knowles GW, et al. PD-L1 Is Not Consti-
tutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to
IFN-gamma and Can Be Expressed in the Tumor Microenvironment. Front Immunol. 2016; 7:581.
https://doi.org/10.3389/fimmu.2016.00581 PMID: 28018348
Expression of heat shock proteins in the marsupial Tasmanian devil
PLOS ONE | https://doi.org/10.1371/journal.pone.0196469 April 27, 2018 22 / 22
